Esomefol-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Esomeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting mucosal healing. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and increasing lower esophageal sphincter tone, which helps alleviate symptoms such as nausea, vomiting, and bloating. The synergistic action of these agents provides effective relief from acid-related symptoms and improves gastrointestinal motility, making Esomefol-DSR suitable for patients with acid reflux accompanied by delayed gastric emptying. The capsule should be administered as prescribed by a healthcare professional, typically before meals, to optimize therapeutic outcomes. Caution is advised in patients with known hypersensitivity to either component, cardiac arrhythmias, or hepatic impairment. Regular monitoring may be necessary during prolonged use. Esomefol-DSR offers a comprehensive approach to managing acid peptic disorders by combining acid suppression with prokinetic activity.